x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DPP-001027
| Product Overview | |
|---|---|
| Species | Zebrafish |
| Expression System | Escherichia coli |
| Format | Liquid |
| Purity | ≥ 95% by HPLC |
| Nature | Recombinant |
| Target Information | |
|---|---|
| Gene Name | il1b |
| UniProt No. | E6N152 |
| Gene ID | 405770 |
| Molecular Weight | 30 kDa including tags |
| Alternative Names | Catabolin; H1; IFN beta inducing factor; IL 1; IL 1 beta; IL-1 beta; IL1; IL1 BETA; IL1B; IL1B_HUMAN; IL1F2; Interleukin 1 beta; Interleukin 1 beta precursor; interleukin 1, beta; Interleukin-1 beta; OAF; Osteoclast activating factor; OTTHUMP00000162031; Preinterleukin 1 beta; Preinterleukin beta; Pro interleukin 1 beta |
| Function | Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. |
| Cellular Localization | Cytoplasm, cytosol. Lysosome. Secreted, exosome. Cytoplasmic vesicle, autophagosome. Secreted. The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome or bacterial flagellin for NLRC4 inflammasome, cleaved and secreted. IL1B lacks any known signal sequence and the pathway(s) of its secretion is(are) not yet fully understood. On the basis of experimental results, several unconventional secretion mechanisms have been proposed. 1. Secretion via secretory lysosomes: a fraction of CASP1 and IL1B precursor may be incorporated, by a yet undefined mechanism, into secretory lysosomes that undergo Ca(2+)-dependent exocytosis with release of mature IL1B. 2. Secretory autophagy: IL1B-containing autophagosomes may fuse with endosomes or multivesicular bodies (MVBs) and then merge with the plasma membrane releasing soluble IL1B or IL1B-containing exosomes. However, autophagy impacts IL1B production at several levels and its role in secretion is still controversial. 3. Secretion via exosomes: ATP-activation of P2RX7 leads to the formation of MVBs containing exosomes with entrapped IL1B, CASP1 and other inflammasome components. These MVBs undergo exocytosis with the release of exosomes. The release of soluble IL1B occurs after the lysis of exosome membranes (By similarity). 4. Secretion by microvesicle shedding: activation of the ATP receptor P2RX7 may induce an immediate shedding of membrane-derived microvesicles containing IL1B and possibly inflammasome components. The cytokine is then released in the extracellular compartment after microvesicle lysis. 5. Release by translocation through permeabilized plasma membrane. This may occur in cells undergoing pyroptosis due to sustained activation of the inflammasome (By similarity). These mechanisms may not be not mutually exclusive. |
| Protein Length | Protein fragment |
| Sequence | CDMHEGIRLEMWTSQHKMKQLVNVIIALNRMKHIKPQSTEFGEKEVLDML MANVIQEREVNVVDSVPSYTKTKNVLQCTICDQYKKSLVRSGGSPHLQAV TLRAGSSDLKVRFSMSTYASPSAPATSAQPVCLGISKSNLYLACSPAEGS APHLVLKEISGSLETIKAGDPNGYDQLLFFRKETGSSINTFESVKCPGWF ISTAYEDSQMVEMDRKDTERIINFELQDKVRI,Belongs to the IL-1 family. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped on dry ice. |
| Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
